BofA lowered the firm’s price target on Johnson & Johnson to $159 from $160 and keeps a Neutral rating on the shares. Following Q4 results, the firm is using a lower sum-of-the-parts valuation applied to its new 2025 EPS estimates, the analyst noted.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson price target lowered to $163 from $175 at Morgan Stanley
- Johnson & Johnson price target lowered to $158 from $160 at Bernstein
- Johnson & Johnson publishes nipocalimab study results in The Lancet Neurology
- Johnson & Johnson price target lowered to $152 from $166 at Wells Fargo
- Johnson & Johnson Reports Strong 2024 Financial Results